| Cash flow (USD) | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 | FY 2020 ended Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Net income | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M |
| Depreciation and amortization | 735.5K | 750.7K | 739.3K | 715.1K | 696.3K | 691.5K |
| Stock-based compensation | 563 | 44.0K | 0 | 0 | ||
| Cash from operations | -8.48M | -6.32M | -5.67M | -5.89M | -8.21M | -6.67M |
| Capital expenditure | -57.0K | -156.6K | -151.7K | -324.3K | -238.8K | -8.6K |
| Free cash flow | -8.54M | -6.47M | -5.82M | -6.22M | -8.45M | -6.67M |
| Cash from investing | -57.0K | -156.6K | -151.7K | -324.3K | ||
| Cash from financing | 5.30M | 3.12M | -94.8K | -234.7K | 15.26M | 17.83M |
| Net change in cash | -3.24M | -3.35M | -5.92M | -6.45M | 6.81M | 11.15M |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.